Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)
2600 Kelly Road
Warrington
Pennsylvania
18976
United States
Tel: 215-488-9300
Fax: 215-488-9301
Website: http://www.discoverylabs.com/
409 articles about Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)
-
Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime
4/27/2023
Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) is a biotechnology company focused on advancing late-stage interventions for acute cardiovascular disorders of acute heart failure and a lead program studying istaroxime in cardiogenic shock.
-
Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
4/24/2023
Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, announced the closing of its previously announced underwritten public offering of 3,686,006 shares of common stock, and warrants to purchase up to 3,686,006 shares of common stock.
-
Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering
4/20/2023
Windtree Therapeutics, Inc. today announced the pricing of its underwritten public offering of 3,686,006 shares of common stock and warrants to purchase up to 3,686,006 shares of common stock (the “Offering”).
-
Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent
4/17/2023
Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, announced that the European Patent Office has granted Patent No. 3599243, providing patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.
-
Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates
4/3/2023
Windtree Therapeutics, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided key business updates.
-
Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime
3/6/2023
Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, is targeting cardiogenic shock as a potential indication for its drug candidate, istaroxime and announces results of a recently completed market study.
-
Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure
2/28/2023
Windtree Therapeutics, Inc. announced that its preclinical stage drug candidates called SERCA2a Activators were featured in a publication in The Journal of Pharmacology and Experimental Therapeutics entitled “Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function.”
-
Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference
2/27/2023
Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, is targeting cardiogenic shock as a potential indication for its drug candidate, istaroxime.
-
Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office
2/24/2023
Windtree Therapeutics, Inc. announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,583,540, providing expanded patent coverage for istaroxime administration.
-
Windtree Therapeutics Announces Reverse Stock Split - February 23, 2023
2/23/2023
Windtree Therapeutics, Inc. today announced that the Company’s Board of Directors has approved a 1-for-50 reverse stock split of its issued and outstanding common stock (the “Reverse Stock Split”).
-
Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants
1/20/2023
Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”) today announced it has entered into warrant inducement offer letters (the “Inducement Offer Letters”) to raise approximately $1.0 million in gross proceeds from the exercise of warrants to purchase 4,808,595 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), in the aggregate.
-
Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance
12/5/2022
Windtree Therapeutics, Inc. today announced that the NASDAQ Stock Market (“Nasdaq”) has granted Windtree an additional 180 days to regain compliance with Nasdaq’s $1.00 minimum bid price rule requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).
-
Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates
11/14/2022
Windtree Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 and provided key business updates.
-
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent
10/25/2022
Windtree Therapeutics, Inc. reported that the United States Patent and Trademark Office has issued a Notice of Allowance of new patent claims for istaroxime administration.
-
Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure
9/28/2022
Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the results of its positive Phase 2 istaroxime study in early cardiogenic shock were published in the European Journal of Heart Failure (https://doi.org/10.1002/ejhf.2629).
-
Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America
9/26/2022
Windtree Therapeutics, Inc. today reported that a late breaking abstract describing dose response data from its positive Phase 2 clinical study of istaroxime in early cardiogenic shock (SEISMiC) will be presented on October 2 at the Heart Failure Society of America Annual Scientific Meeting in Washington, DC.
-
Windtree to Present at the Ladenburg Thalmann Healthcare Conference
9/21/2022
Windtree Therapeutics, Inc. announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and will be available for in-person 1x1 meetings at the upcoming Ladenburg Thalmann Healthcare Conference taking place at the Sofitel Hotel in New York, NY on September 29, 2022.
-
Windtree to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
Windtree Therapeutics, Inc. announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and will be available for virtual 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference taking place on September 12-14, 2022.
-
Money is now flowing into promising platforms for prostate cancer from AdvanCell, mRNA therapeutics from eTheRNA, hepatitis from Bluejay and more.
-
Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement
8/23/2022
Windtree Therapeutics, Inc. announced it has entered into a global licensing agreement with Lee’s Pharmaceutical Limited, and its affiliate Zhaoke Pharmaceutical Co. Ltd., for the development and commercialization of Windtree’s acute pulmonary pipeline treatments KL4 surfactant and drug/device combination, AEROSURF®, for the treatment of preterm infants with respiratory distress syndrome and other potential applications.